ANI PR Wire
15 Mar 2023, 10:30 GMT+10
Geneva [Switzerland], March 15 (ANI/PRNewswire): MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon [DEB SELUTION], versus a limus drug-eluting stent [DES].
SELUTION DeNovo is the largest DEB study ever initiated, involving up to 70 participating sites across 15 countries. Patients are randomized before any vessel preparation to reflect current medical practice and to reduce bias. The objectives of the study are to demonstrate non-inferiority at both one and five years, and superiority for target vessel failure (TVF) at five years.
This study is designed to change medical practice, as the majority of de novo coronary lesions are currently treated with a permanent metallic stent. SELUTION SLR consists of an angioplasty balloon coated with MicroReservoirs containing a mixture of biodegradable polymer and the anti-restenotic drug sirolimus. These MicroReservoirs provide controlled and sustained release of the drug for over 90 days, similar to a DES, but without leaving behind a metal scaffold, which has been associated with a complication rate of 2% annually.
"This is a major milestone for the SELUTION DeNovo trial, as it is now the largest DEB study ever conducted," said Co-Principal Investigator Professor Christian Spaulding, Cardiology Department, European Hospital Georges Pompidou, Assistance Publique Hopitaux de Paris and Paris Cite University, Paris, France. "The study is performed in a true all-comers population and is not just looking at small vessel artery disease. The results will have a major impact on clinical practice."
"This trial has the potential to change medical practice, not only in Europe, but also in the US, China and Japan, benefitting patients around the globe," added Jeffrey B. Jump, MedAlliance Chairman and CEO. "We are currently enrolling US patients in our coronary ISR IDE and BTK studies in the US and Europe."
SELUTION SLR was awarded CE Mark Approval for the treatment of coronary artery disease in May 2020. MedAlliance was the first drug-eluting balloon company to receive FDA Breakthrough Designation status. In addition to the BTK and superficial femoral artery (SFA) indications for which the company received FDA IDE approval in May and August 2022, MedAlliance received coronary in-stent restenosis (ISR) IDE approval in October 2022 and de novo coronary artery lesions approval on January 6th 2023. This will complement the substantial experience that the company has gained with the SELUTION DeNovo trial in Europe.
MedAlliance's unique DEB technology involves MicroReservoirs which contain a mixture of biodegradable polymer intermixed with the anti-restenotic drug sirolimus applied as a coating on the surface of an angioplasty balloon. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days. MedAlliance's proprietary CAT (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and efficiently transferred to adhere to the vessel lumen when delivered via expansion of the balloon.
SELUTION SLR is commercially available in Europe, Asia, the Middle East, and the Americas (outside USA) and most other countries where the CE Mark is recognized. Over 10,000 units have been used for patient treatments in routine clinical practice or as part of coronary clinical trials.
Media Contact:
Richard Kenyon
[email protected]
+44 7831 569940
MedAlliance is a medical technology company which announced a staged acquisition by Cordis in October 2022. Headquartered in Nyon, Switzerland, MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. For further information visit: www.medalliance.com
This story has been provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)
Get a daily dose of South East Asia Post news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to South East Asia Post.
More InformationWASHINGTON, D.C.: The Trump administration has made public a visa decision that would usually be kept private. It did this to send...
MADRID, Spain: Liverpool footballer Diogo Jota and his younger brother, André Silva, have died in a car accident in Spain. Spanish...
LONDON, U.K.: An unrelenting heatwave sweeping across Europe has pushed early summer temperatures to historic highs, triggering deadly...
President Donald Trump's plans to build a space-based Golden Dome missile defense shield have drawn immediate criticism from China,...
NEW YORK CITY, New York: Paramount has agreed to pay US$16 million to settle a lawsuit brought by U.S. President Donald Trump over...
LONDON, U.K.: British Prime Minister Keir Starmer won a vote in Parliament this week to move ahead with changes to the country's welfare...
PALO ALTO/TEL AVIV: The battle for top AI talent has claimed another high-profile casualty—this time at Safe Superintelligence (SSI),...
FRANKLIN, Tennessee: Hundreds of thousands of Nissan and Infiniti vehicles are being recalled across the United States due to a potential...
REDMOND, Washington: Microsoft is the latest tech giant to announce significant job cuts, as the financial strain of building next-generation...
LONDON UK - U.S. stock markets were closed on Friday for Independence Day. Global Forex Markets Wrap Up Friday with Greeback Comeback...
SANTA CLARA, California: Nvidia came within a whisker of making financial history on July 3, briefly surpassing Apple's all-time market...
SACRAMENTO, California: California's multibillion-dollar farms are facing a growing crisis—not from drought or pests, but from a sudden...